文献速递糖尿病性腺与生殖内分泌

孕期口服葡萄糖耐量试验可预测未来糖尿病风险

An Oral Glucose Tolerance Test in Pregnancy Can Serve as a Valuable Predictor for Future Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

中位随访6.7年,共4500例(0.5%)发生T2D;每增加一个异常值,T2D风险显著上升,空腹血糖异常风险高于非空腹异常。既往GDM诊断即使当前OGTT正常也与未来T2D风险显著相关。

要点

  • 孕期OGTT异常值数量越多,未来T2D风险越高,呈阶梯式上升。
  • 空腹血糖异常预测未来T2D的风险高于非空腹血糖异常。
  • 既往GDM诊断即使当前OGTT正常,仍与未来T2D风险显著相关。

核心结论

  • 孕期100克OGTT异常值的数量和类型可强烈预测未来T2D风险。
  • 上述发现有助于指导产后针对性干预和高危女性早期预防预测工具的开发。

研究设计与样本

  • 回顾性研究,数据来自以色列一家大型医疗保健机构。
  • 纳入2000年1月至2022年12月期间末次妊娠时完成100克OGTT、年龄20至50岁且既往无T2D诊断的女性。
  • 主要结局为截至2024年9月发生T2D,采用Cox比例风险模型评估风险。

主要发现

  • 与OGTT全部正常者相比,1个异常值HR 3.45(95%CI: 3.15-3.77),2个异常值HR 4.03(95%CI: 3.69-4.41),3个异常值HR 7.15(95%CI: 6.49-7.88),4个异常值HR 10.60(95%CI: 9.28-12.20)。
  • 空腹血糖异常与未来T2D风险的相关性(HR 5.28;95%CI: 4.83-5.76)高于非空腹值异常(HR 3.03;95%CI: 2.78-3.29)。
  • 既往GDM诊断与未来T2D风险显著相关,即使当前无OGTT异常值。

临床怎么用

  • 可利用孕期OGTT异常值的数量和类型识别未来T2D高危女性。
  • 对既往GDM诊断者即使当前OGTT正常也应重视未来T2D风险。
  • 上述风险分层可指导产后针对性干预和早期预防。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adherence to screening following a pregnancy with gestational diabetes mellitus (GDM) remains low. OBJECTIVE: To assess the risk of future type 2 diabetes (T2D) based on the number and type of abnormal results of a 100-gram oral glucose tolerance test (OGTT) performed during pregnancy. METHODS: This retrospective study used data from a major Israeli healthcare provider. Women aged 20 to 50 years without a prior diagnosis of T2D who had a complete 100-gram OGTT during their last pregnancy between January 2000 and December 2022 were included. The primary outcome was the development of T2D by September 2024. Risk was assessed using Cox proportional hazards models based on the number and type of abnormal OGTT values. RESULTS: The study included 107 889 women (age 34.1 ± 5.2 years; BMI 27.6 ± 5.3 kg/m2). Median follow-up was 6.7 years (IQR 3.3-12.4), totaling 900 000 person-years. T2D developed in 4500 women (0.5%). When compared to women with all OGTT values normal, the risk of T2D rose with each additional abnormal value: hazard ratio (HR) 3.45 (95% CI: 3.15-3.77) for 1 abnormal value, 4.03 (3.69-4.41) for 2 abnormal values, 7.15 (6.49-7.88) for 3, and 10.60 (9.28-12.20) for 4. Abnormal fasting glucose was associated with a higher risk (HR 5.28; 95% CI: 4.83-5.76) than abnormal nonfasting values (HR 3.03; 95% CI: 2.78-3.29). A previous diagnosis of GDM was significantly associated with future T2D risk, even in patients with no current abnormal OGTT values. CONCLUSION: The number and type of abnormal OGTT results strongly predict future T2D. These findings can inform targeted postpartum interventions and predictive tools for early prevention in high-risk women.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Schiller T, Gabay L, Barak O, et al. An Oral Glucose Tolerance Test in Pregnancy Can Serve as a Valuable Predictor for Future Diabetes. J Clin Endocrinol Metab. 2026. PMID: 41004683. doi:10.1210/clinem/dgaf534

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。